J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis
The request is based on findings from the Phase III ASTRO study, which achieved the primary endpoint of clinical remission at week 12.
Drug Development
Zai Lab and Pfizer to commercialise XACDURO in China
FDA issues CRL to Astellas’ IZERVAY sNDA for geographic atrophy
Aclaris Therapeutics secures global rights to Biosion’s antibodies
Novartis strengthens radiopharma leadership with Ratio Therapeutics deal
ReCode to secure funds for cystic fibrosis gene correction treatments
Sandoz’s Afqlir gains EC marketing authorisation for retinal diseases
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
